CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
First Claim
1. A method for determining indications of the prognosis of and aggressiveness of disease in a subject with B cell chronic lymphocytic leukemia (“
- B-CLL”
), the method comprising;
measuring CD38 expression by B-CLL cells in a blood sample from the subject;
determining the percentage of B-CLL cells in the sample that are CD38+; and
comparing said percentage to a cut-off value,wherein a percentage of CD38+ B-CLL cells from the subject that is greater than or equal to the cut-off value indicates a poor prognosis and an aggressive disease course and a percentage of CD38+ B-CLL cells from the subject that is less than the cut-off value indicates an indolent disease course,wherein the cut-off value is determined by;
measuring CD38 expression by B-CLL cells in a blood sample from each of a cohort of B-CLL patients;
determining the percentage of B-CLL cells that are CD38+ in each of the cohort patients;
determining whether the B-CLL in each of the cohort patients is aggressive or indolent; and
plotting the percentage of B-CLL cells that are CD38+ in the cohort patients vs. aggressiveness or indolence in the cohort patients to establish a cut-off value that distinguishes between patients with aggressive disease and patients with indolent disease.
3 Assignments
0 Petitions
Accused Products
Abstract
The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.
88 Citations
10 Claims
-
1. A method for determining indications of the prognosis of and aggressiveness of disease in a subject with B cell chronic lymphocytic leukemia (“
- B-CLL”
), the method comprising;measuring CD38 expression by B-CLL cells in a blood sample from the subject; determining the percentage of B-CLL cells in the sample that are CD38+; and comparing said percentage to a cut-off value, wherein a percentage of CD38+ B-CLL cells from the subject that is greater than or equal to the cut-off value indicates a poor prognosis and an aggressive disease course and a percentage of CD38+ B-CLL cells from the subject that is less than the cut-off value indicates an indolent disease course, wherein the cut-off value is determined by; measuring CD38 expression by B-CLL cells in a blood sample from each of a cohort of B-CLL patients; determining the percentage of B-CLL cells that are CD38+ in each of the cohort patients; determining whether the B-CLL in each of the cohort patients is aggressive or indolent; and plotting the percentage of B-CLL cells that are CD38+ in the cohort patients vs. aggressiveness or indolence in the cohort patients to establish a cut-off value that distinguishes between patients with aggressive disease and patients with indolent disease. - View Dependent Claims (2, 3, 4, 5)
- B-CLL”
-
6. A method for evaluating whether a subject with B cell chronic lymphocytic leukemia (“
- B-CLL”
) should undergo an aggressive course of treatment, the method comprisingmeasuring CD38 expression by B-CLL cells in a blood sample from the subject; determining the percentage of B-CLL cells in the sample that are CD38+; and comparing said percentage to a cut-off value, wherein a percentage of CD38+ B-CLL cells from the subject that is greater than or equal to the cut-off value indicates the subject should undergo an aggressive course of treatment and a percentage of CD38+ B-CLL cells from the subject that is less than the cut-off value indicates the subject should not undergo an aggressive course of treatment, wherein the cut-off value is determined by; measuring CD38 expression by B-CLL cells in a blood sample from each of a cohort of B-CLL patients; determining the percentage of B-CLL cells that are CD38+ in each of the cohort patients; determining whether the B-CLL in each of the cohort patients is aggressive or indolent; and plotting the percentage of B-CLL cells that are CD38+ in the cohort patients vs. aggressiveness or indolence in the cohort patients to establish a cut-off value that distinguishes between patients with aggressive disease and patients with indolent disease. - View Dependent Claims (7, 8, 9, 10)
- B-CLL”
Specification